Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison Martin

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Lancet (London, England)|March 6, 2022
Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsLorcan P McGarvey, Surinder S Birring, Alyn H Morice, et al.
BMJ Open|August 28, 2021
Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPDAllison Martin, Robert J Hancox, Catherina L Chang, et al.
The Lancet. Oncology|August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 studyMoshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.
ERJ Open Research|March 11, 2026
Acute effects of low-dose bisoprolol on lung function and blood pressure in COPD patientsThomas F Bradbury, Allison Martin, Robert J Hancox, et al.
Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.
The Lancet. Oncology|March 6, 2023
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trialBradley J Monk, Krishnansu S Tewari, Coraline Dubot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Lancet (London, England)|March 6, 2022
Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsLorcan P McGarvey, Surinder S Birring, Alyn H Morice, et al.
BMJ Open|August 28, 2021
Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPDAllison Martin, Robert J Hancox, Catherina L Chang, et al.
The Lancet. Oncology|August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 studyMoshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.
ERJ Open Research|March 11, 2026
Acute effects of low-dose bisoprolol on lung function and blood pressure in COPD patientsThomas F Bradbury, Allison Martin, Robert J Hancox, et al.
Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.
The Lancet. Oncology|March 6, 2023
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trialBradley J Monk, Krishnansu S Tewari, Coraline Dubot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Pageof 12